For example, pharmacological inhibition of HSD17β1 improves body weight, HbA1c levels and insulin sensitivity in patients with Type 2 diabetes (40, 41), HSD17β2 depletion in enterocytes increases triglyceride secretion (42), while liver-specific knockout of HSD17β12 leads to weight loss, reduced adipose LD size and increased liver triglyceride in mice (43). Here, HSD17B2 is linked to type 2 diabetes mellitus.